Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01357525 · ClinicalTrials.gov registry record · NA
SBRT for Close or Positive Margins After Resection of Pancreatic Adenocarcinoma
A NA study of Adenocarcinoma of the Pancreas, sponsored by David A. Clump, MD, PhD.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT01357525 is a NA study of Adenocarcinoma of the Pancreas that has completed, run by David A. Clump, MD, PhD. The registered enrollment target is 50 participants, below the 85-participant average among 10 other Adenocarcinoma of the Pancreas trials with a reported enrollment target (41% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01357525, a NA study of Adenocarcinoma of the Pancreas, has completed, sponsored by David A. Clump, MD, PhD.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The current study seeks to further investigate the impact of Stereotactic Body Radiation Therapy following pancreatic resection with a close or positive margin. The investigators hope to improve local control, and through the use of a shortened treatment schedule, allow patients to begin systemic therapy earlier.
Conditions Studied
Interventions
- RADIATION Stereotactic Body Radiation Therapy (SBRT)
Study Locations (1)
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2013-02-06 |
| Est. Completion | 2018-06-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01357525
The ClinicalTrials.gov registry entry for NCT01357525 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 85-participant average among 10 other Adenocarcinoma of the Pancreas trials with a reported enrollment target (41% lower). The listed sponsor is David A. Clump, MD, PhD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Adenocarcinoma of the Pancreas appearing as the primary indexed condition, and to 1 intervention - of which Stereotactic Body Radiation Therapy (SBRT) is the first listed.
NCT01357525 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01357525 about?
NCT01357525 is a clinical study titled "SBRT for Close or Positive Margins After Resection of Pancreatic Adenocarcinoma". The current study seeks to further investigate the impact of Stereotactic Body Radiation Therapy following pancreatic resection with a close or positive margin. The investigators hope to improve local control, and through the use of a shortened treatment schedule, allow patients to begin systemic th...
What is the current status of trial NCT01357525?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2013-02-06. Estimated completion is 2018-06-01.
What conditions does trial NCT01357525 study?
This clinical trial studies the following conditions: Adenocarcinoma of the Pancreas.
What interventions are being tested in trial NCT01357525?
The interventions under investigation include: Stereotactic Body Radiation Therapy (SBRT) (RADIATION).
Who is sponsoring clinical trial NCT01357525?
This trial is sponsored by David A. Clump, MD, PhD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01357525 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenocarcinoma of the Pancreas
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma
RECRUITING · Phase 1
-
Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer
COMPLETED · Phase 2
-
Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
COMPLETED · Phase 3
-
Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer
COMPLETED · Phase 2
-
Perioperative Therapy for Resectable Pancreatic Cancer
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.